You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.
-
Development of a novel highly effective influenza vaccine
SBC: Flugen, Inc. Topic: NIAIDDESCRIPTION provided by applicant Seasonal influenza flu virus an NIAID category C priority pathogen causes widespread infection resulting in at least million cases of severe illness and deaths worldwide Young children and elderly or immunocompromised individuals are typically at greater risk of severe illness or death from influenza Newly emerging strains can result ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
RNA Detection as an Improved Diagnostic Assay for Human Leptospirosis
SBC: L2 Diagnostics, LLC Topic: NIAIDDESCRIPTION provided by applicant Leptospirosis a zoonotic disease is an important public health problem worldwide It is caused by spirochete bacteria belonging to nine species and more than serovars of the genus Leptospira In the US there is increasing awareness of the importance of leptospirosis as the cause of disease among inner city populations military personnel and individuals ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A Multivalent Lyme Disease Vaccine Targeting Tick-Host-Pathogen Interactions
SBC: L2 Diagnostics, LLC Topic: NIAIDDESCRIPTION provided by applicant This proposal seeks to develop a novel vaccine against Lyme disease by targeting Ixodes scapularis proteins critical for Borrelia burgdorferi transmission from the tick to mammalian host Earlier work has identified four tick proteins Salp TRE tHRF and TSLPI that facilitate different steps of spirochete transmission and immunity against these protein ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of Peptide Antibiotic Nucleic Acids
SBC: NUBAD, LLC Topic: NIAIDDESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A novel approach to treat non alcoholic steatohepatitis NASH
SBC: Mitotherapeutix LLC Topic: 300Abstract The Specific Aim of this Phase I STTR proposal is to test the feasibility of treating non alcohol steatohepatitis NASH by increasing mitochondrial metabolism which is the main pathway for lipid catabolism in the liver NASH is a stage of non alcohol fatty liver disease NAFLD that has progressed to a pathological state NASH can lead to cirrhosis leading to liver failure or hepatocel ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
HLS Cyclic CAR peptide a targeted therapy for pulmonary hypertension
SBC: VASCULAR BIOSCIENCES, INC. Topic: NHLBIPUBLIC ABSTRACT This project in response to announcement HLS describes a development program for CARSKNKDC CAR a synthetic cyclic peptide that selectively targets diseased pulmonary vascular endothelium and enhances the therapeutic effect of vasodilator therapies for the treatment of pulmonary hypertension PH PH is a disorder of elevated pulmonary vascular resistance characterized by ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of a POEGMA Aptamer rapid onset anticoagulant that eliminates antigenicity to anti PEG antibodies
SBC: Gateway Bio, Inc. Topic: NHLBIABSTRACT The objective of this STTR proposal is to reformulate a promising PEG aptamer rapid onset anticoagulant ROA by applying a novel PEG like POEGMA polymer brush technology capable of eliminating anti PEG antigenicity The importance of this proposal is highlighted by the early termination of a recent Phase III clinical trial of the original PEG aptamer conjugate in which severe allergic ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
High throughput CRISPR Cas cell line generation using the CellRaft Array platform
SBC: Cell Microsystems, Inc. Topic: NHGRIProject Summary Genome editing technologies such CRISPR Cas provide a rapid and targeted means of both knocking out gene expression and knocking in gene modifications However the current workflow required for CRISPR cell line generation relies on several technologies which reduce throughput efficiency and the overall viability of genome edited cells Cell Microsystems has developed a single ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Picture Me Fit: Engaging Youth in Community-Based Prevention
SBC: Prevention Strategies, LLC Topic: 600DESCRIPTION provided by applicant Approximately one third of all U S adults and children are obese and at risk for a wide range of related chronic health conditions such as cardiovascular disease hypertension diabetes stroke osteoarthritis sleep apnea and certain types of cancer The Center for Disease Control and Prevention CDC and other expert resources recognize that although indivi ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Novel Small Molecule Macrophage Inhibitors for the Treatment of Retinal Diseases
SBC: Eyedesis Biosciences, LLC Topic: NPROJECT SUMMARY ABSTRACT Persistent disease activity PDA in spite of anti vascular endothelial growth factor VEGF therapy remains a significant clinical unmet need for patients with neovascular age related macular degeneration NVAMD The purpose of this STTR Phase I grant application is to develop novel therapies that will be effective for the treatment of PDA associated with NVAMD The cu ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health